Apr 11, 2017
A latest study which has been issued in the American Journal of Respiratory and Critical Care Medicine depicts a novel approach and treatment option for antibiotic resistant bacteria and infectious diseases along with profit for patients and medical care providers.
The extraordinary attempt of eliminating antibodies from the blood stream decreased the effects of chronic infections, determines the researchers from the University of Birmingham and Newcastle University.
The research team identified two patients who have bronchiectasis and suffered from chronic Pseudomonas aeruginosa infections which were resistant to several antibiotics - a 69-year-old female who had bronchiectasis since childhood and a 64-year-old male, who was diagnosed with bronchiectasis at age fifteen.
In the UK, more than 300,000 patients are affected by Bronchiectasis, which is a disease that results in permanent swelling of the airways in the lungs. Patients have unbearable symptoms, such as shortness of breath, chronic cough, chest pain and coughing up blood. Also, this condition affects patients who have crossed the age wherein lung transplantation is possible.
Most commonly in patients suffering from broonchiectasis, may acquire Chronic Pseudomonas aeruginosa lung infections.
Pseudomonas aeruginosa is a typical bacterium that can bring about disease and is termed as a multidrug safe pathogen, perceived for its propelled antibiotic resistance method and linked with chronic maladies.
Both the patients voluntarily took part in the experimental treatment which established on earlier findings from the research group in 2014. They experienced a swift improve in overall heath, increased rate of dependence and better mobility as compared to any point in the earlier two years.
"We needed a brand new way of tackling this problem. Working with kidney and immunology experts, we used a process known as plasmapheresis that is somewhat like kidney dialysis. The plasmapheresis involved the removal, treatment, and return of blood plasma from circulation, and was done 5 times in a week in order to remove antibody from the patients. We then replaced antibodies with those from blood donations. This treatment restored the ability for the patients' blood to kill their infecting Pseudomonas,” said, Bronchiectasis service lead, Newcastle Upon Tyne Hospitals Trust and Senior Lecturer at Newcastle University, Dr Tony De Soyza.
Director of the Institute of Microbiology and Infection at the University of Birmingham, Professor Ian Henderson explained, "These patients had an excess of a particular antibody in the bloodstream. In contrast to the protective effect normally associated with antibody, in these patients the antibody stopped the immune system killing the Pseudomonas aeruginosa bacterium and this worsened the patients' lung disease. Perhaps counter-intuitively, we decided to remove this antibody from the bloodstream and the outcomes were wholly positive."
Apr 11, 2017
All Copyrights reserve worldhealthcarenews.biz 2017.